potential applications for drug design for cystic fibrosis treatment. Based on the crystal structure of human CFTR’s NBD1
approach to construct the human CFTR’s NBD1–NBD2
heterodimeric complex based on the crystal structure of human
CFTR’s NBD1 and a modeled structure of human CFTR’s NBD2 built
by using NBD1 as a mold.
Our method overcomes the backbone clashing
problem and requires noa priori knowledge of the dimeric structure of a homologous protein